Please login to the form below
Nasal polyps
This page shows the latest Nasal polyps news and features for those working in and with pharma, biotech and healthcare.
Tezepelumab effective in severe asthma with comorbid nasal polyps
Amgen’s novel drug offers hope to the one-in-five people with severe asthma who also have nasal polyps. ... L compared to placebo when added to standard-of-care (SoC) in patients with nasal polyps.
Latest news
-
FDA approves new self-injection administration for Xolair
This includes a number of allergic and inflammatory conditions, including moderate-to-severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
-
Sanofi narrows focus, shedding diabetes and cardiovascular research
The drug was first launched for atopic dermatitis in 2016, and has since scored label extensions including adolescent AD patients, asthma and chronic rhinosinusitis with nasal polyps.
-
Dupixent gains can’t keep Sanofi on a growth track
First launched for atopic dermatitis in 2016, label extensions to include adolescent AD patients as well as asthma and chronic rhinosinusitis with nasal polyps helped sales of Regeneron-partnered Dupixent (dupilumab)
-
Sanofi/Regeneron wins another EU approval for Dupixent
This included a 57% and 51% improvement in nasal congestion/obstruction severity, compared to 19% and 15% in the placebo groups in SINUS-24 and SINUS-52. ... It also demonstrated a 33% and 27% reduction in participant’s nasal polyps score compared to a
-
FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps
Nasal polyps can lead to loss of smell and often patients require surgery to remove the polyps,” said the agency’s head of pulmonary, allergy and rheumatology products Sally Seymour. ... Trials of the drug in nasal polyps have showed that it could
FDA approves new self-injection administration for Xolair
Sanofi narrows focus, shedding diabetes and cardiovascular research
Dupixent gains can’t keep Sanofi on a growth track
Sanofi/Regeneron wins another EU approval for Dupixent
FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Exploring the potential of eosinophils
Having too many eosinophils in certain tissues is an important contributor to a range of conditions including severe eosinophilic asthma (SEA), nasal polyps, eosinophilic oesophagitis and rarer, systemic diseases such as ... surgery but whose nasal
Exploring the potential of eosinophils
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- bluebird bio gears up for split
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Accelerating Drug Development Timelines with Big Data Analytics
- A Lucid Group Thirsty Thursday Special: Beautiful Rejects
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US orders 1.4 million more doses of Regeneron antibody cocktail
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Lilly to target difficult-to-treat disease through tie-up with Lycia
- Sanofi/Regeneron bag first approval for Actemra rival sarilumab
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
